The global market for Non-corticosteroid Immunomodulator was valued at US$ 1780 million in the year 2024 and is projected to reach a revised size of US$ 2525 million by 2031, growing at a CAGR of 5.2% during the forecast period.

Non-corticosteroid Immunomodulator Market

The primary types of non-corticosteroid immunomodulators include, calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, and IMDH inhibitors among other drug classes.This is a drug class that inhibits the cell-cycle pathways to limit T- and B-cell proliferation to reduce the cytotoxic response directed toward an organ transplant such as cardiac allograft.Non-corticosteroid immunomodulators play a crucial role in the treatment of autoimmune diseases, inflammatory disorders, and certain types of cancer. Unlike corticosteroids, which have broad immunosuppressive effects, these immunomodulators selectively target specific components of the immune system to restore balance and regulate immune responses.

The global non-corticosteroid immunomodulator market refers to the overall market for medications that modulate the immune system without using corticosteroids. These medications are used to regulate and modify immune responses in various diseases and conditions where an immune system dysfunction is present.

Non-corticosteroid immunomodulators play a crucial role in the treatment of autoimmune diseases, inflammatory disorders, and certain types of cancer. Unlike corticosteroids, which have broad immunosuppressive effects, these immunomodulators selectively target specific components of the immune system to restore balance and regulate immune responses.

The market for non-corticosteroid immunomodulators has been growing significantly due to factors such as the increasing prevalence of autoimmune diseases, the rising demand for targeted therapies, and advancements in biotechnology and drug development. These immunomodulators offer potential benefits such as reduced adverse effects compared to corticosteroids and the ability to provide more precise immune regulation.

The market is segmented based on various factors, including type, application, end-user, and geography. Different types of non-corticosteroid immunomodulators include biologics (monoclonal antibodies, fusion proteins, cytokines), immunosuppressive drugs (calcineurin inhibitors, antimetabolites), and other small molecules.

Applications of non-corticosteroid immunomodulators span across various therapeutic areas, including autoimmune diseases (such as rheumatoid arthritis, multiple sclerosis, psoriasis), inflammatory bowel diseases, organ transplantation, dermatology, and oncology.

Healthcare providers, hospitals, and specialty clinics are the primary end-users of non-corticosteroid immunomodulators. In some cases, these medications may be used in combination with other therapies or as a monotherapy depending on the specific disease or condition.

Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe account for a significant share of the global non-corticosteroid immunomodulator market due to advanced healthcare infrastructure, higher adoption of targeted therapies, and extensive research and development activities. The Asia Pacific region is expected to witness substantial growth owing to the increasing prevalence of autoimmune diseases, improving healthcare facilities, and rising healthcare expenditure.

Key players in the global non-corticosteroid immunomodulator market include pharmaceutical companies, biotechnology firms, and research organizations. These companies invest in research and development, clinical trials, and collaborations to develop novel immunomodulators and expand their product portfolios.

Market trends, growth rates, and competitive landscape may vary across different regions and specific types of non-corticosteroid immunomodulators. Factors such as patent expirations, regulatory approvals, and the emergence of biosimilars can influence the market dynamics.

In summary, the global non-corticosteroid immunomodulator market is expected to witness significant growth in the coming years due to the increasing demand for targeted therapies and the rising prevalence of autoimmune diseases. However, market conditions and growth rates may be influenced by factors such as pricing and reimbursement challenges, competition, and regulatory frameworks.The global non-corticosteroid immunomodulator market refers to the overall market for medications that modulate the immune system without using corticosteroids. These medications are used to regulate and modify immune responses in various diseases and conditions where an immune system dysfunction is present.

This report aims to provide a comprehensive presentation of the global market for Non-corticosteroid Immunomodulator, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-corticosteroid Immunomodulator.

The Non-corticosteroid Immunomodulator market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-corticosteroid Immunomodulator market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-corticosteroid Immunomodulator companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Non-corticosteroid Immunomodulator Market Report

Report Metric	Details
Report Name	Non-corticosteroid Immunomodulator Market
Accounted market size in year	US$ 1780 million
Forecasted market size in 2031	US$ 2525 million
CAGR	5.2%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Calcineurin Inhibitors Antiproliferative Agents mTOR Inhibitors IMDH Inhibitors Others
Segment by Application	Organ Transplantation Atopic Dermatitis Crohn's Disease Ulcerative Colitis Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AbbVie Inc., Bristol Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc, Novartis AG, Amgen Inc., Genentech, Inc., Pfizer Inc., Merck & Co., Inc., Sanofi S.A., Eli Lilly and Company, GlaxoSmithKline PLC, Mylan Laboratories Inc., Glenmark Pharmaceuticals, Inc., Zydus Cadila, Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences, Inc., Boehringer Ingelheim GmbH
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-corticosteroid Immunomodulator company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Non-corticosteroid Immunomodulator Market growing?

Ans: The Non-corticosteroid Immunomodulator Market witnessing a CAGR of 5.2% during the forecast period 2025-2031.

What is the Non-corticosteroid Immunomodulator Market size in 2031?

Ans: The Non-corticosteroid Immunomodulator Market size in 2031 will be US$ 2525 million.

Who are the main players in the Non-corticosteroid Immunomodulator Market report?

Ans: The main players in the Non-corticosteroid Immunomodulator Market are AbbVie Inc., Bristol Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc, Novartis AG, Amgen Inc., Genentech, Inc., Pfizer Inc., Merck & Co., Inc., Sanofi S.A., Eli Lilly and Company, GlaxoSmithKline PLC, Mylan Laboratories Inc., Glenmark Pharmaceuticals, Inc., Zydus Cadila, Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences, Inc., Boehringer Ingelheim GmbH

What are the Application segmentation covered in the Non-corticosteroid Immunomodulator Market report?

Ans: The Applications covered in the Non-corticosteroid Immunomodulator Market report are Organ Transplantation, Atopic Dermatitis, Crohn's Disease, Ulcerative Colitis, Others

What are the Type segmentation covered in the Non-corticosteroid Immunomodulator Market report?

Ans: The Types covered in the Non-corticosteroid Immunomodulator Market report are Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitors, IMDH Inhibitors, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Non-corticosteroid Immunomodulator Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Calcineurin Inhibitors

1.2.3 Antiproliferative Agents

1.2.4 mTOR Inhibitors

1.2.5 IMDH Inhibitors

1.2.6 Others

1.3 Market by Application

1.3.1 Global Non-corticosteroid Immunomodulator Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Organ Transplantation

1.3.3 Atopic Dermatitis

1.3.4 Crohn's Disease

1.3.5 Ulcerative Colitis

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Non-corticosteroid Immunomodulator Market Perspective (2020-2031)

2.2 Global Non-corticosteroid Immunomodulator Growth Trends by Region

2.2.1 Global Non-corticosteroid Immunomodulator Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Non-corticosteroid Immunomodulator Historic Market Size by Region (2020-2025)

2.2.3 Non-corticosteroid Immunomodulator Forecasted Market Size by Region (2026-2031)

2.3 Non-corticosteroid Immunomodulator Market Dynamics

2.3.1 Non-corticosteroid Immunomodulator Industry Trends

2.3.2 Non-corticosteroid Immunomodulator Market Drivers

2.3.3 Non-corticosteroid Immunomodulator Market Challenges

2.3.4 Non-corticosteroid Immunomodulator Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Non-corticosteroid Immunomodulator Players by Revenue

3.1.1 Global Top Non-corticosteroid Immunomodulator Players by Revenue (2020-2025)

3.1.2 Global Non-corticosteroid Immunomodulator Revenue Market Share by Players (2020-2025)

3.2 Global Non-corticosteroid Immunomodulator Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Non-corticosteroid Immunomodulator Revenue

3.4 Global Non-corticosteroid Immunomodulator Market Concentration Ratio

3.4.1 Global Non-corticosteroid Immunomodulator Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Non-corticosteroid Immunomodulator Revenue in 2024

3.5 Global Key Players of Non-corticosteroid Immunomodulator Head office and Area Served

3.6 Global Key Players of Non-corticosteroid Immunomodulator, Product and Application

3.7 Global Key Players of Non-corticosteroid Immunomodulator, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Non-corticosteroid Immunomodulator Breakdown Data by Type

4.1 Global Non-corticosteroid Immunomodulator Historic Market Size by Type (2020-2025)

4.2 Global Non-corticosteroid Immunomodulator Forecasted Market Size by Type (2026-2031)

5 Non-corticosteroid Immunomodulator Breakdown Data by Application

5.1 Global Non-corticosteroid Immunomodulator Historic Market Size by Application (2020-2025)

5.2 Global Non-corticosteroid Immunomodulator Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Non-corticosteroid Immunomodulator Market Size (2020-2031)

6.2 North America Non-corticosteroid Immunomodulator Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Non-corticosteroid Immunomodulator Market Size by Country (2020-2025)

6.4 North America Non-corticosteroid Immunomodulator Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Non-corticosteroid Immunomodulator Market Size (2020-2031)

7.2 Europe Non-corticosteroid Immunomodulator Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Non-corticosteroid Immunomodulator Market Size by Country (2020-2025)

7.4 Europe Non-corticosteroid Immunomodulator Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Non-corticosteroid Immunomodulator Market Size (2020-2031)

8.2 Asia-Pacific Non-corticosteroid Immunomodulator Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Non-corticosteroid Immunomodulator Market Size by Region (2020-2025)

8.4 Asia-Pacific Non-corticosteroid Immunomodulator Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Non-corticosteroid Immunomodulator Market Size (2020-2031)

9.2 Latin America Non-corticosteroid Immunomodulator Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Non-corticosteroid Immunomodulator Market Size by Country (2020-2025)

9.4 Latin America Non-corticosteroid Immunomodulator Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Non-corticosteroid Immunomodulator Market Size (2020-2031)

10.2 Middle East & Africa Non-corticosteroid Immunomodulator Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Non-corticosteroid Immunomodulator Market Size by Country (2020-2025)

10.4 Middle East & Africa Non-corticosteroid Immunomodulator Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AbbVie Inc.

11.1.1 AbbVie Inc. Company Details

11.1.2 AbbVie Inc. Business Overview

11.1.3 AbbVie Inc. Non-corticosteroid Immunomodulator Introduction

11.1.4 AbbVie Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.1.5 AbbVie Inc. Recent Development

11.2 Bristol Myers Squibb Company

11.2.1 Bristol Myers Squibb Company Company Details

11.2.2 Bristol Myers Squibb Company Business Overview

11.2.3 Bristol Myers Squibb Company Non-corticosteroid Immunomodulator Introduction

11.2.4 Bristol Myers Squibb Company Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.2.5 Bristol Myers Squibb Company Recent Development

11.3 Celgene Corporation

11.3.1 Celgene Corporation Company Details

11.3.2 Celgene Corporation Business Overview

11.3.3 Celgene Corporation Non-corticosteroid Immunomodulator Introduction

11.3.4 Celgene Corporation Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.3.5 Celgene Corporation Recent Development

11.4 Janssen Pharmaceuticals, Inc

11.4.1 Janssen Pharmaceuticals, Inc Company Details

11.4.2 Janssen Pharmaceuticals, Inc Business Overview

11.4.3 Janssen Pharmaceuticals, Inc Non-corticosteroid Immunomodulator Introduction

11.4.4 Janssen Pharmaceuticals, Inc Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.4.5 Janssen Pharmaceuticals, Inc Recent Development

11.5 Novartis AG

11.5.1 Novartis AG Company Details

11.5.2 Novartis AG Business Overview

11.5.3 Novartis AG Non-corticosteroid Immunomodulator Introduction

11.5.4 Novartis AG Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.5.5 Novartis AG Recent Development

11.6 Amgen Inc.

11.6.1 Amgen Inc. Company Details

11.6.2 Amgen Inc. Business Overview

11.6.3 Amgen Inc. Non-corticosteroid Immunomodulator Introduction

11.6.4 Amgen Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.6.5 Amgen Inc. Recent Development

11.7 Genentech, Inc.

11.7.1 Genentech, Inc. Company Details

11.7.2 Genentech, Inc. Business Overview

11.7.3 Genentech, Inc. Non-corticosteroid Immunomodulator Introduction

11.7.4 Genentech, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.7.5 Genentech, Inc. Recent Development

11.8 Pfizer Inc.

11.8.1 Pfizer Inc. Company Details

11.8.2 Pfizer Inc. Business Overview

11.8.3 Pfizer Inc. Non-corticosteroid Immunomodulator Introduction

11.8.4 Pfizer Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.8.5 Pfizer Inc. Recent Development

11.9 Merck & Co., Inc.

11.9.1 Merck & Co., Inc. Company Details

11.9.2 Merck & Co., Inc. Business Overview

11.9.3 Merck & Co., Inc. Non-corticosteroid Immunomodulator Introduction

11.9.4 Merck & Co., Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.9.5 Merck & Co., Inc. Recent Development

11.10 Sanofi S.A.

11.10.1 Sanofi S.A. Company Details

11.10.2 Sanofi S.A. Business Overview

11.10.3 Sanofi S.A. Non-corticosteroid Immunomodulator Introduction

11.10.4 Sanofi S.A. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.10.5 Sanofi S.A. Recent Development

11.11 Eli Lilly and Company

11.11.1 Eli Lilly and Company Company Details

11.11.2 Eli Lilly and Company Business Overview

11.11.3 Eli Lilly and Company Non-corticosteroid Immunomodulator Introduction

11.11.4 Eli Lilly and Company Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.11.5 Eli Lilly and Company Recent Development

11.12 GlaxoSmithKline PLC

11.12.1 GlaxoSmithKline PLC Company Details

11.12.2 GlaxoSmithKline PLC Business Overview

11.12.3 GlaxoSmithKline PLC Non-corticosteroid Immunomodulator Introduction

11.12.4 GlaxoSmithKline PLC Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.12.5 GlaxoSmithKline PLC Recent Development

11.13 Mylan Laboratories Inc.

11.13.1 Mylan Laboratories Inc. Company Details

11.13.2 Mylan Laboratories Inc. Business Overview

11.13.3 Mylan Laboratories Inc. Non-corticosteroid Immunomodulator Introduction

11.13.4 Mylan Laboratories Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.13.5 Mylan Laboratories Inc. Recent Development

11.14 Glenmark Pharmaceuticals, Inc.

11.14.1 Glenmark Pharmaceuticals, Inc. Company Details

11.14.2 Glenmark Pharmaceuticals, Inc. Business Overview

11.14.3 Glenmark Pharmaceuticals, Inc. Non-corticosteroid Immunomodulator Introduction

11.14.4 Glenmark Pharmaceuticals, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.14.5 Glenmark Pharmaceuticals, Inc. Recent Development

11.15 Novartis AG

11.15.1 Novartis AG Company Details

11.15.2 Novartis AG Business Overview

11.15.3 Novartis AG Non-corticosteroid Immunomodulator Introduction

11.15.4 Novartis AG Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.15.5 Novartis AG Recent Development

11.16 Zydus Cadila

11.16.1 Zydus Cadila Company Details

11.16.2 Zydus Cadila Business Overview

11.16.3 Zydus Cadila Non-corticosteroid Immunomodulator Introduction

11.16.4 Zydus Cadila Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.16.5 Zydus Cadila Recent Development

11.17 Takeda Pharmaceutical Company Limited

11.17.1 Takeda Pharmaceutical Company Limited Company Details

11.17.2 Takeda Pharmaceutical Company Limited Business Overview

11.17.3 Takeda Pharmaceutical Company Limited Non-corticosteroid Immunomodulator Introduction

11.17.4 Takeda Pharmaceutical Company Limited Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.17.5 Takeda Pharmaceutical Company Limited Recent Development

11.18 AstraZeneca PLC

11.18.1 AstraZeneca PLC Company Details

11.18.2 AstraZeneca PLC Business Overview

11.18.3 AstraZeneca PLC Non-corticosteroid Immunomodulator Introduction

11.18.4 AstraZeneca PLC Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.18.5 AstraZeneca PLC Recent Development

11.19 Gilead Sciences, Inc.

11.19.1 Gilead Sciences, Inc. Company Details

11.19.2 Gilead Sciences, Inc. Business Overview

11.19.3 Gilead Sciences, Inc. Non-corticosteroid Immunomodulator Introduction

11.19.4 Gilead Sciences, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.19.5 Gilead Sciences, Inc. Recent Development

11.20 Boehringer Ingelheim GmbH

11.20.1 Boehringer Ingelheim GmbH Company Details

11.20.2 Boehringer Ingelheim GmbH Business Overview

11.20.3 Boehringer Ingelheim GmbH Non-corticosteroid Immunomodulator Introduction

11.20.4 Boehringer Ingelheim GmbH Revenue in Non-corticosteroid Immunomodulator Business (2020-2025)

11.20.5 Boehringer Ingelheim GmbH Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Bristol Myers Squibb Company

GlaxoSmithKline PLC

Glenmark Pharmaceuticals, Inc.

Pfizer Inc

Mylan Laboratories, Inc.

Novartis

Zydus Cadila

AbbVie

Celgene Corporation

Janssen Pharmaceuticals, Inc.

Eli Lilly and Company

Takeda Pharmaceutical Company Limited

Astrazeneca plc

Gilead Sciences Inc

Boehringer Ingelheim GmbH

List of Tables

Table 1. Global Non-corticosteroid Immunomodulator Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Calcineurin Inhibitors

Table 3. Key Players of Antiproliferative Agents

Table 4. Key Players of mTOR Inhibitors

Table 5. Key Players of IMDH Inhibitors

Table 6. Key Players of Others

Table 7. Global Non-corticosteroid Immunomodulator Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Non-corticosteroid Immunomodulator Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Non-corticosteroid Immunomodulator Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Non-corticosteroid Immunomodulator Market Share by Region (2020-2025)

Table 11. Global Non-corticosteroid Immunomodulator Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Non-corticosteroid Immunomodulator Market Share by Region (2026-2031)

Table 13. Non-corticosteroid Immunomodulator Market Trends

Table 14. Non-corticosteroid Immunomodulator Market Drivers

Table 15. Non-corticosteroid Immunomodulator Market Challenges

Table 16. Non-corticosteroid Immunomodulator Market Restraints

Table 17. Global Non-corticosteroid Immunomodulator Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Non-corticosteroid Immunomodulator Market Share by Players (2020-2025)

Table 19. Global Top Non-corticosteroid Immunomodulator Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-corticosteroid Immunomodulator as of 2024)

Table 20. Ranking of Global Top Non-corticosteroid Immunomodulator Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Non-corticosteroid Immunomodulator Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Non-corticosteroid Immunomodulator, Headquarters and Area Served

Table 23. Global Key Players of Non-corticosteroid Immunomodulator, Product and Application

Table 24. Global Key Players of Non-corticosteroid Immunomodulator, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Non-corticosteroid Immunomodulator Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Non-corticosteroid Immunomodulator Revenue Market Share by Type (2020-2025)

Table 28. Global Non-corticosteroid Immunomodulator Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Non-corticosteroid Immunomodulator Revenue Market Share by Type (2026-2031)

Table 30. Global Non-corticosteroid Immunomodulator Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Non-corticosteroid Immunomodulator Revenue Market Share by Application (2020-2025)

Table 32. Global Non-corticosteroid Immunomodulator Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Non-corticosteroid Immunomodulator Revenue Market Share by Application (2026-2031)

Table 34. North America Non-corticosteroid Immunomodulator Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Non-corticosteroid Immunomodulator Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Non-corticosteroid Immunomodulator Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Non-corticosteroid Immunomodulator Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Non-corticosteroid Immunomodulator Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Non-corticosteroid Immunomodulator Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Non-corticosteroid Immunomodulator Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Non-corticosteroid Immunomodulator Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Non-corticosteroid Immunomodulator Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Non-corticosteroid Immunomodulator Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Non-corticosteroid Immunomodulator Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Non-corticosteroid Immunomodulator Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Non-corticosteroid Immunomodulator Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Non-corticosteroid Immunomodulator Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Non-corticosteroid Immunomodulator Market Size by Country (2026-2031) & (US$ Million)

Table 49. AbbVie Inc. Company Details

Table 50. AbbVie Inc. Business Overview

Table 51. AbbVie Inc. Non-corticosteroid Immunomodulator Product

Table 52. AbbVie Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 53. AbbVie Inc. Recent Development

Table 54. Bristol Myers Squibb Company Company Details

Table 55. Bristol Myers Squibb Company Business Overview

Table 56. Bristol Myers Squibb Company Non-corticosteroid Immunomodulator Product

Table 57. Bristol Myers Squibb Company Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 58. Bristol Myers Squibb Company Recent Development

Table 59. Celgene Corporation Company Details

Table 60. Celgene Corporation Business Overview

Table 61. Celgene Corporation Non-corticosteroid Immunomodulator Product

Table 62. Celgene Corporation Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 63. Celgene Corporation Recent Development

Table 64. Janssen Pharmaceuticals, Inc Company Details

Table 65. Janssen Pharmaceuticals, Inc Business Overview

Table 66. Janssen Pharmaceuticals, Inc Non-corticosteroid Immunomodulator Product

Table 67. Janssen Pharmaceuticals, Inc Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 68. Janssen Pharmaceuticals, Inc Recent Development

Table 69. Novartis AG Company Details

Table 70. Novartis AG Business Overview

Table 71. Novartis AG Non-corticosteroid Immunomodulator Product

Table 72. Novartis AG Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 73. Novartis AG Recent Development

Table 74. Amgen Inc. Company Details

Table 75. Amgen Inc. Business Overview

Table 76. Amgen Inc. Non-corticosteroid Immunomodulator Product

Table 77. Amgen Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 78. Amgen Inc. Recent Development

Table 79. Genentech, Inc. Company Details

Table 80. Genentech, Inc. Business Overview

Table 81. Genentech, Inc. Non-corticosteroid Immunomodulator Product

Table 82. Genentech, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 83. Genentech, Inc. Recent Development

Table 84. Pfizer Inc. Company Details

Table 85. Pfizer Inc. Business Overview

Table 86. Pfizer Inc. Non-corticosteroid Immunomodulator Product

Table 87. Pfizer Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 88. Pfizer Inc. Recent Development

Table 89. Merck & Co., Inc. Company Details

Table 90. Merck & Co., Inc. Business Overview

Table 91. Merck & Co., Inc. Non-corticosteroid Immunomodulator Product

Table 92. Merck & Co., Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 93. Merck & Co., Inc. Recent Development

Table 94. Sanofi S.A. Company Details

Table 95. Sanofi S.A. Business Overview

Table 96. Sanofi S.A. Non-corticosteroid Immunomodulator Product

Table 97. Sanofi S.A. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 98. Sanofi S.A. Recent Development

Table 99. Eli Lilly and Company Company Details

Table 100. Eli Lilly and Company Business Overview

Table 101. Eli Lilly and Company Non-corticosteroid Immunomodulator Product

Table 102. Eli Lilly and Company Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 103. Eli Lilly and Company Recent Development

Table 104. GlaxoSmithKline PLC Company Details

Table 105. GlaxoSmithKline PLC Business Overview

Table 106. GlaxoSmithKline PLC Non-corticosteroid Immunomodulator Product

Table 107. GlaxoSmithKline PLC Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 108. GlaxoSmithKline PLC Recent Development

Table 109. Mylan Laboratories Inc. Company Details

Table 110. Mylan Laboratories Inc. Business Overview

Table 111. Mylan Laboratories Inc. Non-corticosteroid Immunomodulator Product

Table 112. Mylan Laboratories Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 113. Mylan Laboratories Inc. Recent Development

Table 114. Glenmark Pharmaceuticals, Inc. Company Details

Table 115. Glenmark Pharmaceuticals, Inc. Business Overview

Table 116. Glenmark Pharmaceuticals, Inc. Non-corticosteroid Immunomodulator Product

Table 117. Glenmark Pharmaceuticals, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 118. Glenmark Pharmaceuticals, Inc. Recent Development

Table 119. Novartis AG Company Details

Table 120. Novartis AG Business Overview

Table 121. Novartis AG Non-corticosteroid Immunomodulator Product

Table 122. Novartis AG Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 123. Novartis AG Recent Development

Table 124. Zydus Cadila Company Details

Table 125. Zydus Cadila Business Overview

Table 126. Zydus Cadila Non-corticosteroid Immunomodulator Product

Table 127. Zydus Cadila Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 128. Zydus Cadila Recent Development

Table 129. Takeda Pharmaceutical Company Limited Company Details

Table 130. Takeda Pharmaceutical Company Limited Business Overview

Table 131. Takeda Pharmaceutical Company Limited Non-corticosteroid Immunomodulator Product

Table 132. Takeda Pharmaceutical Company Limited Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 133. Takeda Pharmaceutical Company Limited Recent Development

Table 134. AstraZeneca PLC Company Details

Table 135. AstraZeneca PLC Business Overview

Table 136. AstraZeneca PLC Non-corticosteroid Immunomodulator Product

Table 137. AstraZeneca PLC Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 138. AstraZeneca PLC Recent Development

Table 139. Gilead Sciences, Inc. Company Details

Table 140. Gilead Sciences, Inc. Business Overview

Table 141. Gilead Sciences, Inc. Non-corticosteroid Immunomodulator Product

Table 142. Gilead Sciences, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 143. Gilead Sciences, Inc. Recent Development

Table 144. Boehringer Ingelheim GmbH Company Details

Table 145. Boehringer Ingelheim GmbH Business Overview

Table 146. Boehringer Ingelheim GmbH Non-corticosteroid Immunomodulator Product

Table 147. Boehringer Ingelheim GmbH Revenue in Non-corticosteroid Immunomodulator Business (2020-2025) & (US$ Million)

Table 148. Boehringer Ingelheim GmbH Recent Development

Table 149. Research Programs/Design for This Report

Table 150. Key Data Information from Secondary Sources

Table 151. Key Data Information from Primary Sources

Table 152. Authors List of This Report

List of Figures

Figure 1. Non-corticosteroid Immunomodulator Picture

Figure 2. Global Non-corticosteroid Immunomodulator Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Non-corticosteroid Immunomodulator Market Share by Type: 2024 VS 2031

Figure 4. Calcineurin Inhibitors Features

Figure 5. Antiproliferative Agents Features

Figure 6. mTOR Inhibitors Features

Figure 7. IMDH Inhibitors Features

Figure 8. Others Features

Figure 9. Global Non-corticosteroid Immunomodulator Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Non-corticosteroid Immunomodulator Market Share by Application: 2024 VS 2031

Figure 11. Organ Transplantation Case Studies

Figure 12. Atopic Dermatitis Case Studies

Figure 13. Crohn's Disease Case Studies

Figure 14. Ulcerative Colitis Case Studies

Figure 15. Others Case Studies

Figure 16. Non-corticosteroid Immunomodulator Report Years Considered

Figure 17. Global Non-corticosteroid Immunomodulator Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 18. Global Non-corticosteroid Immunomodulator Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 19. Global Non-corticosteroid Immunomodulator Market Share by Region: 2024 VS 2031

Figure 20. Global Non-corticosteroid Immunomodulator Market Share by Players in 2024

Figure 21. Global Top Non-corticosteroid Immunomodulator Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-corticosteroid Immunomodulator as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by Non-corticosteroid Immunomodulator Revenue in 2024

Figure 23. North America Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. North America Non-corticosteroid Immunomodulator Market Share by Country (2020-2031)

Figure 25. United States Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Canada Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Non-corticosteroid Immunomodulator Market Share by Country (2020-2031)

Figure 29. Germany Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Non-corticosteroid Immunomodulator Market Share by Region (2020-2031)

Figure 37. China Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Japan Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. South Korea Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. India Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Australia Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Non-corticosteroid Immunomodulator Market Share by Country (2020-2031)

Figure 45. Mexico Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Brazil Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Non-corticosteroid Immunomodulator Market Share by Country (2020-2031)

Figure 49. Turkey Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. UAE Non-corticosteroid Immunomodulator Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. AbbVie Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 53. Bristol Myers Squibb Company Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 54. Celgene Corporation Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 55. Janssen Pharmaceuticals, Inc Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 56. Novartis AG Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 57. Amgen Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 58. Genentech, Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 59. Pfizer Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 60. Merck & Co., Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 61. Sanofi S.A. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 62. Eli Lilly and Company Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 63. GlaxoSmithKline PLC Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 64. Mylan Laboratories Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 65. Glenmark Pharmaceuticals, Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 66. Novartis AG Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 67. Zydus Cadila Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 68. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 69. AstraZeneca PLC Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 70. Gilead Sciences, Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 71. Boehringer Ingelheim GmbH Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2020-2025)

Figure 72. Bottom-up and Top-down Approaches for This Report

Figure 73. Data Triangulation

Figure 74. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-3J10777

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global No-Sting Antiseptic Cleansing Spray Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14C19097

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Therapeutic Support Surface Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9U19104

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Enteral Medicine Straw Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-31N10509

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Non-corticosteroid Immunomodulator Market Research Report 2025

Published Date: January 2025

Report Code: QYRE-Auto-26B10641

Global Non-corticosteroid Immunomodulator Market Research Report 2025

FEATURED COMPANIES

Non-corticosteroid Immunomodulator Market Size

Non-corticosteroid Immunomodulator Market

Scope of Non-corticosteroid Immunomodulator Market Report

Chapter Outline

FAQ for this report

How fast is Non-corticosteroid Immunomodulator Market growing?

What is the Non-corticosteroid Immunomodulator Market size in 2031?

Who are the main players in the Non-corticosteroid Immunomodulator Market report?

What are the Application segmentation covered in the Non-corticosteroid Immunomodulator Market report?

What are the Type segmentation covered in the Non-corticosteroid Immunomodulator Market report?

FEATURED COMPANIES

RELATED REPORTS

$5800

Enterprise User

$5800

Enterprise User

$5800

Enterprise User

$5800

Enterprise User